60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy

作者：J. Neal, N. Pavlakis, S-W. Kim, Y. Goto, S.M. Lim, G. Mountzios, E. Fountzilas, A. Mochalova, D.C.C. Christoph, A. Bearz, X. Quantin, R. Palmero, V. Antic, Eun Mi Chun, Tirupathi Rao Edubilli, Yi-Chan Lin, M. Huseni, C. Scheffold, P. Vervaet, T. Newsom-Davis · 发表于：Journal of Thoracic Oncology · 年份：2023 · DOI：10.1016/s1556-0864(23)00260-5 · 被引用次数：31 · 研究领域：Cancer Immunotherapy and Biomarkers、Advanced Breast Cancer Therapies、Cancer Genomics and Diagnostics